iBio Reports Primate Data Showing IBIO-610 Preserves Lean Mass in Weight Loss Combination
Biotechnology firm iBio, Inc. (IBIO) released data from an eight-week study in obese non-human primates evaluating its drug candidate IBIO-610 in combination with semaglutide. The trial showed that combining IBIO-610 with twice-weekly semaglutide significantly reduced muscle loss compared to semaglutide alone. Lean mass accounted for 6% of overall weight loss in the combination group versus 22% for semaglutide by itself, while fat comprised 93% of weight lost compared to 77%.
The study also evaluated the biological mechanisms and longevity of the treatment. A single intravenous dose of IBIO-610 achieved near-complete inhibition of active Activin E and reduced serum active Activin E levels by 97% at week eight. Additionally, the compound exhibited a 33.2-day half-life in non-human primates, suggesting the potential for a twice-yearly dosing schedule in humans.
Following the release of the study data, shares of iBio, Inc. rose 3.70% to $0.9032. Investors will be observing the company's progress as it moves toward clinical development, with first-in-human studies for IBIO-610 scheduled to begin in the first half of 2027.
Key points
- In an eight-week primate study, IBIO-610 plus semaglutide limited lean mass loss to 6% of total weight lost compared to 22% for semaglutide alone.
- Fat accounted for 93% of weight lost in the combination group compared to 77% with semaglutide by itself.
- A single intravenous dose yielded a 97% reduction in serum active Activin E at week eight and demonstrated a 33.2-day half-life.
- iBio, Inc. plans to start its first clinical trials in humans during the first half of 2027.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
What did iBio report regarding IBIO-610?
iBio reported non-human primate study data showing IBIO-610 combined with semaglutide preserved muscle mass and shifted 93% of weight loss to fat over eight weeks.
How does IBIO-610 affect dosing schedules?
The drug candidate demonstrated a 33.2-day half-life in primates, which may support a projected twice-yearly dosing schedule in humans.
When will human trials for IBIO-610 begin?
iBio plans to launch its first-in-human clinical studies for IBIO-610 in the first half of 2027.